This study evaluated the relationship between nocturnal polyuria (NP - excessive nighttime urine production) and 24-hour blood pressure fluctuations in patients with urinary symptoms. The data suggested that patients with NP had a poorer reduction of nighttime blood pressure. 

This study evaluated whether the Vigor 2020, a new vacuum erection device (VED), is effective for the management of erectile dysfunction (ED). The main finding was that Vigor 2020 was effective for men with ED. 

This study evaluated the effectiveness and safety of giving a double dose of tamsulosin (Flomax; 0.8 mg per day) to patients with benign prostatic hyperplasia (BPH) who did not respond to the standard tamsulosin dose (0.4 mg per day) and who could not have prostate surgery. The data showed that a double dose of tamsulosin was an effective and safe temporary option for these patients.

This study reviewed the effectiveness and safety of L-arginine and Pycnogenol^® (PAL) in the treatment of male erectile dysfunction (ED). The data showed that the combination of PAL had a significant effect on improving sexual function in patients with mild to moderate ED.

This study investigated the effectiveness of RestoreX on penile length and erectile function in patients after prostate surgery. The data showed that RestoreX treatment improves penile length and erectile function in men who underwent prostate surgery.

This study evaluated the effectiveness and safety of platelet-rich plasma (PRP) injections for the treatment of patients with mild and moderate erectile dysfunction (ED). The data showed that PRP was a safe and promising treatment for improving mild to moderate ED.

This study evaluated the effectiveness and safety of Quisqualis indica (Rangoon creeper or Chinese honeysuckle; a type of plant) extract for the treatment of patients with lower urinary tract symptoms (LUTS). The data showed that Quisqualis indica extract was safe and effective for the treatment of these patients.

This study evaluated the effectiveness and safety of aprocitentan (ACT-132577) for lowering blood pressure (BP) in patients with resistant or uncontrolled hypertension (high BP). The data showed that aprocitentan was effective in lowering the BP after 4 weeks with a sustained effect after 40 weeks compared to a placebo with manageable side effects in these patients.

This study evaluated the effectiveness and safety of high-dose rosuvastatin (Crestor) combined with telmisartan (Micardis) or amlodipine (Norvasc) on glucose metabolism in patients with atherosclerotic cardiovascular disease (ASCVD), hypertension (high blood pressure), and impaired fasting glucose (IFG or prediabetes). The data showed that telmisartan significantly reduced the fasting glucose levels to normal glucose levels and prevented the new onset of diabetes in these patients.

This study evaluated the outcomes of single-pass versus multiple-pass during aquablation in patients with lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH). The data showed that treatment with multiple passes during aquablation improved the urinary outcomes compared to a single pass in these patients.